Raymond James Keeps 'Strong Buy' Rating on Relay Therapeutics but Lowers Price Target to $19

Raymond James maintains "Strong Buy" rating for Relay Therapeutics (RLAY) but lowers price target from $29 to $19, a 34.48% decrease. The average analyst price target for RLAY is $13.30, with an average target implying an upside of 321.55% from the current price of $3.16. The estimated GF Value for RLAY in one year is $19.06, suggesting a 504.12% upside from the current price.

Raymond James has revised its price target for Relay Therapeutics (RLAY), lowering it from $29.00 to $19.00. Despite this adjustment, the investment firm maintains a "Strong Buy" rating, indicating a potential upside of 34.48% from the stock's previous close. The average analyst price target for RLAY stands at $13.30, implying an average upside of 321.55% from the current price of $3.16. The estimated GF Value for RLAY in one year is $19.06, suggesting a potential upside of 504.12% from the current price [1].

The move by Raymond James reflects the company's recent financial performance and market conditions. Relay Therapeutics reported its second-quarter earnings data, which surpassed analyst expectations. The company achieved an adjusted earnings per share (EPS) of $0.02, beating the consensus estimate of $0.01. Revenue for the quarter reached $45 million, marking a 10% organic growth and exceeding consensus expectations by 10%. This strong performance has led to a positive outlook from multiple analysts, including RBC Capital, which raised its price target for RLAY from $10 to $15, maintaining an Outperform rating [2].

The lowered price target by Raymond James suggests a cautious approach to the stock's valuation. However, the "Strong Buy" rating indicates confidence in the company's long-term growth prospects. The investment firm believes that Relay Therapeutics' innovative approach to drug discovery and development positions it well for future success. The company's involvement in critical therapeutic areas, such as cancer and rare diseases, further supports this optimistic view.

Investors should closely monitor the company's future earnings reports and any updates from Raymond James to stay informed about potential changes in the stock's valuation. The current market conditions and the company's competitive landscape will also play a significant role in determining the stock's performance in the coming quarters.

References:
[1] https://www.marketbeat.com/instant-alerts/raymond-james-financial-lowers-godaddy-nysegddy-price-target-to-17500-2025-08-08/
[2] https://www.investing.com/news/analyst-ratings/kratos-defense--security-stock-price-target-doubled-by-raymond-james-93CH-4181392